References
- American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304.
- Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
- Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995;152:1107-36.
- Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006;3:285-92.
- Nagai S, Nagao T, Kitaichi M, Izumi T. Clinical courses of asymptomatic cases with idiopathic pulmonary fibrosis and a histology of usual interstitial pneumonia. Eur Respir J 1998;11:131s.
- Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157:199-203.
- Nagai S, Kitaichi M, Hamada K, Nagao T, Hoshino Y, Miki H, et al. Hospital-based historical cohort study of 234 histologically proven Japanese patients with IPF. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:209-14.
- Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-42.
- Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:543-8.
- Jegal Y, Kim DS, Shim TS, Lim CM, Lee SD, Koh Y, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005;171:639-44.
- Nicholson AG, Colby TV, Dubois RM, Hansell DM, Wells AU. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000;162:2213-7.
- Travis WD, Matsui K, Moss J, Ferrans VJ. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 2000;24:19-33.
- Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125-33.
- Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353: 2229-42.
- Scientific Committee of the Korean Academy of Tuberculosis and Respiratory Diseases. 2008 National Survey of Idiopathic Interstitial Pneumonia in Korea. Tuberc Respir Dis 2009;66:141-51.
- Panos RJ, Mortenson RL, Niccoli SA, King TE Jr. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990;88:396-404.
- Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 1993;103:1808-12.
- Ambrosini V, Cancellieri A, Chilosi M, Zompatori M, Trisolini R, Saragoni L, et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J 2003;22:821-6.
- Akira M, Hamada H, Sakatani M, Kobayashi C, Nishioka M, Yamamoto S. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am J Roentgenol 1997;168:79-83.
- Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-7.
- Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006;27: 143-50.
- Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest 2005;128:3310-5.
- Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005;128:1475-82.
- Kondoh Y, Taniguchi H, Yokoi T, Nishiyama O, Ohishi T, Kato T, et al. Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia. Eur Respir J 2005;25:528-33.
- Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005;142(12 Pt 1):963-7.
- King TE Jr, Schwarz MI, Brown K, Tooze JA, Colby TV, Waldron JA Jr, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001;164:1025-32.
- Flaherty KR, Colby TV, Travis WD, Toews GB, Mumford J, Murray S, et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med 2003;167:1410-5.
- Nicholson AG, Fulford LG, Colby TV, du Bois RM, Hansell DM, Wells AU. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002;166:173-7.
- World Health Organization. Obesity: preventing and managing the global epidemic. Report on a WHO Consultation. WHO Technical Report Series No. 894. Geneva: World Health Organization; 2000.
- Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, et al. American Thoracic Society/ European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006;173: 1390-413.
- Stark LJ, Powers SW. Behavioral aspects of nutrition in children with cystic fibrosis. Curr Opin Pulm Med 2005;11:539-42.
- Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med 2006;173:475-82.
- Cano NJ, Pichard C, Roth H, Court-Fortune I, Cynober L, Gerard-Boncompain M, et al. C-reactive protein and body mass index predict outcome in end-stage respiratory failure. Chest 2004;126:540-6.
- Alakhras M, Decker PA, Nadrous HF, Collazo-Clavell M, Ryu JH. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. Chest 2007;131: 1448-53.
- Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-83.
- Savino W. The thymus gland is a target in malnutrition. Eur J Clin Nutr 2002;56 Suppl 3:S46-9.
- Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003;167:735-40.
- Mejia M, Carrillo G, Rojas-Serrano J, Estrada A, Suarez T, Alonso D, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009;136:10-5.
- Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005;26:586-93.
Cited by
- Respiratory and lower limb muscle function in interstitial lung disease vol.13, pp.2, 2012, https://doi.org/10.1177/1479972315626014
- Current best practice in rehabilitation in interstitial lung disease vol.11, pp.2, 2012, https://doi.org/10.1177/1753465816676048
- Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis vol.23, pp.3, 2017, https://doi.org/10.18553/jmcp.2017.23.3-b.s17
- Prognostic factors and outcomes in Japanese lung transplant candidates with interstitial lung disease vol.12, pp.8, 2012, https://doi.org/10.1371/journal.pone.0183171
- Efficacy of pirfenidone for the treatment of pulmonary fibrosis : An updated systematic review protocol of randomized controlled trial vol.98, pp.17, 2019, https://doi.org/10.1097/md.0000000000015407
- Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry vol.5, pp.3, 2012, https://doi.org/10.1183/23120541.00170-2018
- Assessing Patterns of Palliative Care Referral and Location of Death in Patients with Idiopathic Pulmonary Fibrosis: A Sixteen-Year Single-Center Retrospective Cohort Study vol.22, pp.5, 2012, https://doi.org/10.1089/jpm.2018.0400
- Comparison of disease progression subgroups in idiopathic pulmonary fibrosis vol.19, pp.1, 2012, https://doi.org/10.1186/s12890-019-0996-2
- The Interstitial Lung Disease-Gender-Age-Physiology Index Can Predict the Prognosis in Surgically Resected Patients with Interstitial Lung Disease and Concomitant Lung Cancer vol.99, pp.1, 2020, https://doi.org/10.1159/000502849
- Nutrition in Patients with Idiopathic Pulmonary Fibrosis: Critical Issues Analysis and Future Research Directions vol.12, pp.4, 2020, https://doi.org/10.3390/nu12041131
- Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact vol.56, pp.1, 2012, https://doi.org/10.1183/13993003.02135-2019
- Pleuroparenchymal fibroelastosis in patients with idiopathic pulmonary fibrosis vol.25, pp.10, 2012, https://doi.org/10.1111/resp.13796
- Body mass index and in-hospital mortality in patients with acute exacerbation of idiopathic pulmonary fibrosis vol.7, pp.2, 2012, https://doi.org/10.1183/23120541.00037-2021